A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 ...

A study led by Roswell Park provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in patients with recurrent ovarian ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

PDC*line Pharma, a clinical-stage biotech company developing a new class of immunotherapies for cancers, presented the primary results of its phase I/II clinical trial for PDC*lung01, an innovative ...

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

Patients with stages I to III TNBC (n = 469) who previously received neoadjuvant chemotherapy (n = 321) or neoadjuvant ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

Anixa's focus on breast and ovarian cancer immunotherapies shows promise but lacks substantial data. Find out why I ...